Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : si-544
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SelectION Reports Safety Results from SAD Stage of SI-544 Phase Ib trial
Details : si-544, the Company´s drug candidate, is blocking Kv1.3, a specific ion channel involved in the activation and proliferation of TEM cells. It is being developed in Phase 1 trial in atopic dermatitis patients.
Product Name : si-544
Product Type : Peptide
Upfront Cash : Inapplicable
May 30, 2023
Lead Product(s) : si-544
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable